|
Insider Trading: Progenics Pharmaceuticals Inc
Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Progenics Pharmaceuticals Inc in the last 24 months are illustrated in figures 1 and 2. Table 1 shows the monthly insider trading data of Progenics Pharmaceuticals Inc since year 2005. Table 2 shows the detailed insider transactions of Progenics Pharmaceuticals Inc since 2005.
The reporting company's ticker symbol is PGNX.
The reporting company's CIK number is 835887.
The total value of stock buying since 2005 is $0.
The total value of stock sales is $19,635,864.
The total value of stock exercises is $7,335,355.
1 year stock price chart,
1 day stock price chart
opopp opopopop
Figure 1. Monthly insider transaction values at Progenics Pharmaceuticals Inc (PGNX) in the past 24 months.
The trade values of insider stock buys, sales, and option exercises are in logarithmic scale
as shown on the right axis labels.
The detailed monthly and daily insider transactions are listed in the 2 tables below.
11 12 01 2007 02 03 04 05 06 07 08 09 10 11 12 01 2008 02 03 04 05 06 07 08 09 10 -
Figure 2. Average prices of insider buys, sales, and option exercises at Progenics Pharmaceuticals Inc (PGNX) in the past 24 months. See table 2 for insider transaction details.
11 12 01 2007 02 03 04 05 06 07 08 09 10 11 12 01 2008 02 03 04 05 06 07 08 09 10 -
Table 1. Monthly summaries of insider stock purchases, sales, and option exercises
for Progenics Pharmaceuticals Inc (PGNX).
Trading Period
year-month |
Insider Buying
Shares Value ($) |
Insider Sales
Shares Value ($) |
Option Exercises
Shares Value ($) |
| 2008-10 | 0 | 0 | 62,500 | 577,625 | 37,563 | 245,280 |
| 2008-09 | 0 | 0 | 1,000 | 15,000 | 1,000 | 12,290 |
| 2008-08 | 0 | 0 | 1,000 | 16,465 | 51,000 | 493,540 |
| 2008-07 | 0 | 0 | 11,000 | 175,942 | 27,040 | 298,518 |
| 2008-06 | 0 | 0 | 1,000 | 16,397 | 1,000 | 12,290 |
| 2008-05 | 0 | 0 | 1,000 | 15,000 | 8,500 | 52,514 |
| 2008-04 | 0 | 0 | 1,000 | 15,000 | 14,792 | 102,212 |
| 2008-03 | 0 | 0 | 1,000 | 15,300 | 8,500 | 47,247 |
| 2008-02 | 0 | 0 | 1,000 | 16,440 | 1,000 | 12,290 |
| 2008-01 | 0 | 0 | 1,000 | 18,120 | 5,986 | 88,793 |
| 2007-12 | 0 | 0 | 6,000 | 115,351 | 6,000 | 42,040 |
| 2007-10 | 0 | 0 | 27,000 | 616,692 | 49,797 | 646,256 |
| 2007-09 | 0 | 0 | 24,000 | 565,908 | 24,000 | 127,920 |
| 2007-08 | 0 | 0 | 26,000 | 578,410 | 26,000 | 158,735 |
| 2007-07 | 0 | 0 | 26,000 | 560,602 | 36,536 | 422,853 |
| 2007-06 | 0 | 0 | 14,000 | 305,067 | 14,000 | 94,775 |
| 2007-05 | 0 | 0 | 26,000 | 613,961 | 26,000 | 158,735 |
| 2007-04 | 0 | 0 | 30,000 | 769,362 | 34,393 | 384,615 |
| 2007-03 | 0 | 0 | 36,000 | 898,714 | 36,000 | 198,735 |
| 2007-02 | 0 | 0 | 62,000 | 1,858,002 | 62,000 | 332,680 |
| 2007-01 | 0 | 0 | 38,500 | 1,062,826 | 51,232 | 478,080 |
| 2006-12 | 0 | 0 | 50,000 | 1,344,816 | 50,000 | 258,300 |
| 2006-11 | 0 | 0 | 52,000 | 1,433,357 | 52,000 | 262,735 |
| 2006-10 | 0 | 0 | 33,000 | 789,341 | 38,192 | 371,915 |
| 2006-09 | 0 | 0 | 29,000 | 672,731 | 29,000 | 147,920 |
| 2006-08 | 0 | 0 | 29,000 | 609,252 | 29,000 | 147,920 |
| 2006-07 | 0 | 0 | 29,000 | 658,453 | 43,904 | 532,625 |
| 2006-06 | 0 | 0 | 37,025 | 803,159 | 15,000 | 73,300 |
| 2006-05 | 0 | 0 | 39,000 | 897,840 | 39,000 | 182,600 |
| 2006-04 | 0 | 0 | 25,000 | 639,447 | 29,231 | 271,182 |
| 2006-03 | 0 | 0 | 32,000 | 905,380 | 32,000 | 154,600 |
| 2006-02 | 0 | 0 | 50,500 | 1,407,893 | 49,000 | 318,850 |
| 2006-01 | 0 | 0 | 8,000 | 221,064 | 12,528 | 203,010 |
| 2005-09 | 0 | 0 | 5,000 | 125,000 | 0 | 0 |
| 2005-06 | 0 | 0 | 15,150 | 301,947 | 0 | 0 |
Go to page: 1
2
Table 2. Detailed insider stock purchases, sales, and option exercises
for Progenics Pharmaceuticals Inc (PGNX)
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2008-10-23 | Jacobson Paul F (Director) | Sale | 27,000 | 9.05 | 244,458 |
| 2008-10-22 | Jacobson Paul F (Director) | Sale | 35,500 | 9.38 | 333,167 |
| 2008-10-01 | Baker Mark Robert (General Counsel) | Option Exercise | 4,786 | 6.53 | 31,252 |
| 2008-10-01 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Exercise | 8,768 | 6.53 | 57,254 |
| 2008-10-01 | Olson William C (VP, Research & Development) | Option Exercise | 2,968 | 6.53 | 19,380 |
| 2008-10-01 | Mckinney Robert A (Chief Financial Officer) | Option Exercise | 3,638 | 6.53 | 23,756 |
| 2008-10-01 | Israel Robert J (Sr. VP, Medical Affairs) | Option Exercise | 4,882 | 6.53 | 31,878 |
| 2008-09-03 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 1,000 | 15.00 | 15,000 |
| 2008-09-03 | Israel Robert J (Sr. VP, Medical Affairs) | Option Exercise | 1,000 | 12.29 | 12,290 |
| 2008-08-28 | Briner Kurt W (Director) | Option Exercise | 50,000 | 9.62 | 481,250 |
| 2008-08-01 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 1,000 | 16.46 | 16,465 |
| 2008-08-01 | Israel Robert J (Sr. VP, Medical Affairs) | Option Exercise | 1,000 | 12.29 | 12,290 |
| 2008-07-15 | Jacobson Paul F (Director) | Sale | 10,000 | 16.04 | 160,350 |
| 2008-07-15 | Jacobson Paul F (Director) | Option Exercise | 10,000 | 6.88 | 68,820 |
| 2008-07-01 | Baker Mark Robert (General Counsel) | Option Exercise | 4,865 | 13.64 | 66,358 |
| 2008-07-01 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Exercise | 2,921 | 13.64 | 39,842 |
| 2008-07-01 | Olson William C (VP, Research & Development) | Option Exercise | 2,296 | 13.64 | 31,317 |
| 2008-07-01 | Mckinney Robert A (Chief Financial Officer) | Option Exercise | 2,921 | 13.64 | 39,842 |
| 2008-07-01 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 1,000 | 15.59 | 15,592 |
| 2008-07-01 | Israel Robert J (Sr. VP, Medical Affairs) | Option Exercise | 4,037 | 12.96 | 52,339 |
| 2008-06-02 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 1,000 | 16.40 | 16,397 |
| 2008-06-02 | Israel Robert J (Sr. VP, Medical Affairs) | Option Exercise | 1,000 | 12.29 | 12,290 |
| 2008-05-27 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 1,000 | 15.00 | 15,000 |
| 2008-05-27 | Israel Robert J (Sr. VP, Medical Affairs) | Option Exercise | 1,000 | 12.29 | 12,290 |
| 2008-05-14 | Dalton Mark F (Director) | Option Exercise | 7,500 | 5.36 | 40,224 |
| 2008-04-25 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 1,000 | 15.00 | 15,000 |
| 2008-04-25 | Israel Robert J (Sr. VP, Medical Affairs) | Option Exercise | 1,000 | 12.29 | 12,290 |
| 2008-04-01 | Baker Mark Robert (General Counsel) | Option Exercise | 2,533 | 6.52 | 16,515 |
| 2008-04-01 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Exercise | 1,914 | 6.52 | 12,479 |
| 2008-04-01 | Kremer Alton B (VP, Clinical Research) | Option Exercise | 3,153 | 6.52 | 20,557 |
| 2008-04-01 | Olson William C (VP, Research & Development) | Option Exercise | 1,576 | 6.52 | 10,275 |
| 2008-04-01 | Mckinney Robert A (Chief Financial Officer) | Option Exercise | 1,914 | 6.52 | 12,479 |
| 2008-04-01 | Israel Robert J (Sr. VP, Medical Affairs) | Option Exercise | 2,702 | 6.52 | 17,617 |
| 2008-03-28 | Scheinberg David A (Director) | Option Exercise | 7,500 | 4.66 | 34,957 |
| 2008-03-03 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 1,000 | 15.30 | 15,300 |
| 2008-03-03 | Israel Robert J (Sr. VP, Medical Affairs) | Option Exercise | 1,000 | 12.29 | 12,290 |
| 2008-02-01 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 1,000 | 16.44 | 16,440 |
| 2008-02-01 | Israel Robert J (Sr. VP, Medical Affairs) | Option Exercise | 1,000 | 12.29 | 12,290 |
| 2008-01-02 | Baker Mark Robert (General Counsel) | Option Exercise | 916 | 15.33 | 14,042 |
| 2008-01-02 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Exercise | 692 | 15.33 | 10,608 |
| 2008-01-02 | Kremer Alton B (VP, Clinical Research) | Option Exercise | 1,139 | 15.36 | 17,495 |
| 2008-01-02 | Olson William C (VP, Research & Development) | Option Exercise | 570 | 15.33 | 8,738 |
| 2008-01-02 | Mckinney Robert A (Chief Financial Officer) | Option Exercise | 692 | 15.33 | 10,608 |
| 2008-01-02 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 1,000 | 18.12 | 18,120 |
| 2008-01-02 | Israel Robert J (Sr. VP, Medical Affairs) | Option Exercise | 1,977 | 13.81 | 27,302 |
| 2007-12-06 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 1,000 | 20.00 | 20,000 |
| 2007-12-06 | Israel Robert J (Sr. VP, Medical Affairs) | Option Exercise | 1,000 | 13.75 | 13,750 |
| 2007-12-03 | Olson William C (VP, Research & Development) | Sale | 4,000 | 19.03 | 76,112 |
| 2007-12-03 | Olson William C (VP, Research & Development) | Option Exercise | 4,000 | 4.00 | 16,000 |
| 2007-12-03 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 1,000 | 19.24 | 19,239 |
| 2007-12-03 | Israel Robert J (Sr. VP, Medical Affairs) | Option Exercise | 1,000 | 12.29 | 12,290 |
| 2007-10-15 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 15,000 | 23.49 | 352,380 |
| 2007-10-15 | Maddon Paul J (Chief Executive Officer/CSO) | Option Exercise | 15,000 | 5.33 | 79,950 |
| 2007-10-01 | Baker Mark Robert (General Counsel) | Option Exercise | 1,496 | 19.03 | 28,468 |
| 2007-10-01 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Exercise | 4,058 | 19.03 | 77,222 |
| 2007-10-01 | Kremer Alton B (VP, Clinical Research) | Option Exercise | 4,656 | 19.03 | 88,602 |
| 2007-10-01 | Olson William C (VP, Research & Development) | Option Exercise | 932 | 19.03 | 17,734 |
| 2007-10-01 | Mckinney Robert A (Chief Financial Officer) | Option Exercise | 1,130 | 19.03 | 21,502 |
| 2007-10-01 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 22.03 | 264,312 |
| 2007-10-01 | Maddon Paul J (Chief Executive Officer/CSO) | Option Exercise | 13,995 | 12.18 | 170,459 |
| 2007-10-01 | Israel Robert J (Sr. VP, Medical Affairs) | Option Exercise | 1,596 | 19.03 | 30,370 |
| 2007-09-17 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 23.39 | 280,728 |
| 2007-09-17 | Maddon Paul J (Chief Executive Officer/CSO) | Option Exercise | 12,000 | 5.33 | 63,960 |
| 2007-09-04 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 23.76 | 285,180 |
| 2007-09-04 | Maddon Paul J (Chief Executive Officer/CSO) | Option Exercise | 12,000 | 5.33 | 63,960 |
| 2007-08-15 | Boyd Thomas A (Sr. VP, Product Dev.) | Sale | 2,000 | 22.88 | 45,766 |
| 2007-08-15 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Exercise | 2,000 | 15.41 | 30,815 |
| 2007-08-15 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 23.16 | 277,860 |
| 2007-08-15 | Maddon Paul J (Chief Executive Officer/CSO) | Option Exercise | 12,000 | 5.33 | 63,960 |
| 2007-08-01 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 21.23 | 254,784 |
| 2007-08-01 | Maddon Paul J (Chief Executive Officer/CSO) | Option Exercise | 12,000 | 5.33 | 63,960 |
| 2007-07-16 | Boyd Thomas A (Sr. VP, Product Dev.) | Sale | 2,000 | 21.51 | 43,019 |
| 2007-07-16 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Exercise | 2,000 | 15.41 | 30,815 |
| 2007-07-16 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 21.46 | 257,472 |
| 2007-07-16 | Maddon Paul J (Chief Executive Officer/CSO) | Option Exercise | 12,000 | 5.33 | 63,960 |
| 2007-07-02 | Baker Mark Robert (General Counsel) | Option Exercise | 3,451 | 18.71 | 64,568 |
| 2007-07-02 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Exercise | 545 | 18.71 | 10,196 |
| 2007-07-02 | Kremer Alton B (VP, Clinical Research) | Option Exercise | 852 | 18.71 | 15,940 |
| 2007-07-02 | Olson William C (VP, Research & Development) | Option Exercise | 1,546 | 18.71 | 28,925 |
| 2007-07-02 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 21.68 | 260,111 |
| 2007-07-02 | Maddon Paul J (Chief Executive Officer/CSO) | Option Exercise | 13,986 | 12.02 | 168,111 |
| 2007-07-02 | Israel Robert J (Sr. VP, Medical Affairs) | Option Exercise | 2,156 | 18.71 | 40,338 |
| 2007-06-15 | Boyd Thomas A (Sr. VP, Product Dev.) | Sale | 2,000 | 22.03 | 44,055 |
| 2007-06-15 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Exercise | 2,000 | 15.41 | 30,815 |
| 2007-06-01 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 21.75 | 261,012 |
| 2007-06-01 | Maddon Paul J (Chief Executive Officer/CSO) | Option Exercise | 12,000 | 5.33 | 63,960 |
| 2007-05-15 | Boyd Thomas A (Sr. VP, Product Dev.) | Sale | 2,000 | 21.90 | 43,805 |
| 2007-05-15 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Exercise | 2,000 | 15.41 | 30,815 |
| 2007-05-15 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 21.90 | 262,800 |
| 2007-05-15 | Maddon Paul J (Chief Executive Officer/CSO) | Option Exercise | 12,000 | 5.33 | 63,960 |
| 2007-05-01 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 25.61 | 307,356 |
| 2007-05-01 | Maddon Paul J (Chief Executive Officer/CSO) | Option Exercise | 12,000 | 5.33 | 63,960 |
| 2007-04-16 | Boyd Thomas A (Sr. VP, Product Dev.) | Sale | 4,000 | 26.94 | 107,748 |
| 2007-04-16 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Exercise | 4,000 | 15.41 | 61,630 |
| 2007-04-16 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 26.80 | 321,588 |
| 2007-04-16 | Maddon Paul J (Chief Executive Officer/CSO) | Option Exercise | 12,000 | 5.33 | 63,960 |
| 2007-04-02 | Baker Mark Robert (General Counsel) | Option Exercise | 621 | 20.13 | 12,500 |
| 2007-04-02 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Exercise | 2,018 | 20.13 | 40,622 |
| 2007-04-02 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 23.85 | 286,152 |
| 2007-04-02 | Maddon Paul J (Chief Executive Officer/CSO) | Option Exercise | 13,754 | 12.73 | 175,088 |
| 2007-03-15 | Boyd Thomas A (Sr. VP, Product Dev.) | Sale | 2,000 | 22.78 | 45,568 |
| 2007-03-15 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Exercise | 2,000 | 15.41 | 30,815 |
| 2007-03-15 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 22.95 | 275,424 |
| 2007-03-15 | Maddon Paul J (Chief Executive Officer/CSO) | Option Exercise | 12,000 | 5.33 | 63,960 |
| 2007-03-01 | Scheinberg David A (Director) | Sale | 10,000 | 25.99 | 259,890 |
| 2007-03-01 | Scheinberg David A (Director) | Option Exercise | 10,000 | 4.00 | 40,000 |
| 2007-03-01 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 26.49 | 317,832 |
| 2007-03-01 | Maddon Paul J (Chief Executive Officer/CSO) | Option Exercise | 12,000 | 5.33 | 63,960 |
| 2007-02-15 | Boyd Thomas A (Sr. VP, Product Dev.) | Sale | 4,000 | 29.97 | 119,896 |
| 2007-02-15 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Exercise | 4,000 | 17.19 | 68,760 |
| 2007-02-15 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 29.89 | 358,716 |
| 2007-02-15 | Maddon Paul J (Chief Executive Officer/CSO) | Option Exercise | 12,000 | 5.33 | 63,960 |
| 2007-02-12 | Mckinney Robert A (Chief Financial Officer) | Sale | 4,000 | 29.48 | 117,908 |
| 2007-02-12 | Mckinney Robert A (Chief Financial Officer) | Option Exercise | 4,000 | 4.00 | 16,000 |
| 2007-02-02 | Scheinberg David A (Director) | Sale | 30,000 | 30.10 | 902,850 |
| 2007-02-02 | Scheinberg David A (Director) | Option Exercise | 30,000 | 4.00 | 120,000 |
| 2007-02-01 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 29.89 | 358,632 |
| 2007-02-01 | Maddon Paul J (Chief Executive Officer/CSO) | Option Exercise | 12,000 | 5.33 | 63,960 |
| 2007-01-29 | Mckinney Robert A (Chief Financial Officer) | Sale | 4,000 | 29.72 | 118,872 |
| 2007-01-29 | Mckinney Robert A (Chief Financial Officer) | Option Exercise | 4,000 | 4.00 | 16,000 |
| 2007-01-29 | Baker Charles A (Director) | Sale | 2,500 | 30.02 | 75,050 |
| 2007-01-29 | Baker Charles A (Director) | Option Exercise | 2,500 | 19.50 | 48,750 |
| 2007-01-16 | Mckinney Robert A (Chief Financial Officer) | Sale | 4,000 | 28.79 | 115,160 |
| 2007-01-16 | Mckinney Robert A (Chief Financial Officer) | Option Exercise | 4,000 | 4.00 | 16,000 |
| 2007-01-16 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 28.58 | 342,912 |
| 2007-01-16 | Maddon Paul J (Chief Executive Officer/CSO) | Option Exercise | 12,000 | 5.33 | 63,960 |
| 2007-01-08 | Scheinberg David A (Director) | Option Exercise | 8,000 | 4.00 | 32,000 |
| 2007-01-03 | Baker Mark Robert (General Counsel) | Option Exercise | 571 | 21.88 | 12,493 |
| 2007-01-03 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Exercise | 428 | 21.88 | 9,364 |
| 2007-01-03 | Kremer Alton B (VP, Clinical Research) | Option Exercise | 686 | 21.88 | 15,009 |
| 2007-01-03 | Olson William C (VP, Research & Development) | Option Exercise | 362 | 21.88 | 7,920 |
| 2007-01-03 | Mckinney Robert A (Chief Financial Officer) | Sale | 4,000 | 25.68 | 102,708 |
| 2007-01-03 | Mckinney Robert A (Chief Financial Officer) | Option Exercise | 4,428 | 12.94 | 57,298 |
| 2007-01-03 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 25.68 | 308,124 |
| 2007-01-03 | Maddon Paul J (Chief Executive Officer/CSO) | Option Exercise | 13,614 | 13.60 | 185,218 |
| 2007-01-03 | Israel Robert J (Sr. VP, Medical Affairs) | Option Exercise | 643 | 21.88 | 14,068 |
| 2006-12-15 | Boyd Thomas A (Sr. VP, Product Dev.) | Sale | 2,000 | 26.05 | 52,100 |
| 2006-12-15 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Exercise | 2,000 | 17.19 | 34,380 |
| 2006-12-15 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 26.14 | 313,668 |
| 2006-12-15 | Maddon Paul J (Chief Executive Officer/CSO) | Option Exercise | 12,000 | 5.33 | 63,960 |
| 2006-12-11 | Mckinney Robert A (Chief Financial Officer) | Sale | 4,000 | 27.75 | 110,988 |
| 2006-12-11 | Mckinney Robert A (Chief Financial Officer) | Option Exercise | 4,000 | 4.00 | 16,000 |
| 2006-12-04 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 5,000 | 28.00 | 140,000 |
| 2006-12-04 | Israel Robert J (Sr. VP, Medical Affairs) | Option Exercise | 5,000 | 4.00 | 20,000 |
| 2006-12-01 | Scheinberg David A (Director) | Sale | 10,000 | 27.15 | 271,493 |
| 2006-12-01 | Scheinberg David A (Director) | Option Exercise | 10,000 | 4.00 | 40,000 |
| 2006-12-01 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 26.83 | 322,002 |
| 2006-12-01 | Maddon Paul J (Chief Executive Officer/CSO) | Option Exercise | 12,000 | 5.33 | 63,960 |
| 2006-12-01 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 5,000 | 26.91 | 134,565 |
| 2006-12-01 | Israel Robert J (Sr. VP, Medical Affairs) | Option Exercise | 5,000 | 4.00 | 20,000 |
Go to page: 1
2
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Progenics Pharmaceuticals Inc (symbol PGNX,
CIK number 835887) see
the Securities and Exchange Commission (SEC) website.
|
|
